This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Asia Bio Partnering Forum
2 days in-person. 2 days virtually.

April 26–27, 2023 | Singapore
May 4–5, 2023 | Virtual

SapiensBio Inc


SapiensBio approach uses Machine Learning technology to analyze the complexity of the human pathobiology, at the level at the cellular level and their interactions in the pathological tissue/organ and compare those in the non-disease tissue/organ. We try to understand the changes occurring at the level of individual cells and the changes in the cell population. Studies using 3-dimensional tissue/organ cultures of human pathological samples are them used to validate the selected targets using biological tools and small molecules. SapiensBio drug discovery platform, Sapiencia, has been designed to mine novel targets and generate new chemical matter. It fully. Integrates machine learning system and wet lab experimentation in a single workflow. It starts with the analysis of biological data from pathological samples together with genetic/genomic data to identify relevant targets, which are further evaluated based on their biology and other parameters. Relevance of the target to the pathology is validate buy traditional wet lab experiments using biological tools and small molecule inhibitors identified by in silico screening and synthesized by SapiensBio Med Chem group. Following lead identification SapiensBio scientists take advantage of in silico tools to go through lead optimization in a process that parallel those traditionally use in drug discovery but including experimental studies using human organoids from healthy and pathological samples. SapiensBio is posted to be a Research Oriented, Drug Discovery company with a focus in bringing innovated programs to address clear unmet medical needs. We are currently focusing in two therapy areas, Fibrosis and Neurodegenerative diseases. By taken advantages of its Sapiencia platform, SapiensBio is hoping to drastically reduce the time from target validation to clinical candidate selection. The goal is to be able to complete this process in around 20 months for any particular target.